The key role of phosphoinositide 3-kinase (PI3K) pathway in different cellular processes and several disorders, together with the presence of targetable proteins, opened the way to promising studies for the development of small molecule inhibitors. Despite the high expectation, the shift of PI3K inhibitors to the clinic met several limitations due to the emergence of dose-limiting, on-target adverse effects. In this review, we will summarize the main issues and recent advances in PI3K inhibitors clinical trials. The effort to develop isoform-specific inhibitors, together with novel therapeutic strategies aimed at reducing the toxicity and adverse effects, opened a new promising era for PI3K inhibitors. In addition, we will focus on the recent emergence of class II and III PI3K inhibitors, which helped to define their class I non-redundant role.

Targeting PI3K signaling in cancer: Challenges and advances

De Santis M. C.;Gulluni F.;Campa C. C.;Martini M.;Hirsch E.
2019

Abstract

The key role of phosphoinositide 3-kinase (PI3K) pathway in different cellular processes and several disorders, together with the presence of targetable proteins, opened the way to promising studies for the development of small molecule inhibitors. Despite the high expectation, the shift of PI3K inhibitors to the clinic met several limitations due to the emergence of dose-limiting, on-target adverse effects. In this review, we will summarize the main issues and recent advances in PI3K inhibitors clinical trials. The effort to develop isoform-specific inhibitors, together with novel therapeutic strategies aimed at reducing the toxicity and adverse effects, opened a new promising era for PI3K inhibitors. In addition, we will focus on the recent emergence of class II and III PI3K inhibitors, which helped to define their class I non-redundant role.
1871
2
361
366
Combination therapy; Pathway inhibitors; PI3K; Systemic toxicity; Animals; Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Phosphoinositide-3 Kinase Inhibitors
De Santis M.C.; Gulluni F.; Campa C.C.; Martini M.; Hirsch E.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1767078
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 42
social impact